MARKET

OTLK

OTLK

Outlook Therapeutics Inc
NASDAQ
1.980
+0.160
+8.79%
After Hours: 1.970 -0.01 -0.51% 17:05 12/29 EST
OPEN
1.850
PREV CLOSE
1.820
HIGH
1.980
LOW
1.780
VOLUME
5.74M
TURNOVER
--
52 WEEK HIGH
3.390
52 WEEK LOW
0.7900
MARKET CAP
126.95M
P/E (TTM)
-1.1037
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at OTLK last week (1222-1226)?
Weekly Report · 13h ago
Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again
Seeking Alpha · 21h ago
Outlook Therapeutics Grants Stock Options to New Employees
Reuters · 3d ago
Outlook Therapeutics Announces New Employment Inducement Grants
Barchart · 3d ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—12/24/25
TipRanks · 5d ago
Outlook Therapeutics: Strengthened Case for ONS-5010 Drives Attractive Risk/Reward and Increased $10 Price Target
TipRanks · 5d ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—12/23/25
TipRanks · 6d ago
GE Vernova To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga · 12/22 13:33
More
About OTLK
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.

Webull offers Outlook Therapeutics Inc stock information, including NASDAQ: OTLK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTLK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OTLK stock methods without spending real money on the virtual paper trading platform.